Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research

By: via Benzinga
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that an article on final data for the Phase 1 portion of ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.